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Abstract
The discovery of protein biomarkers that reflect the biological state of the body is of vital importance to disease management. Urine is an ideal 
source of biomarkers that provides a non-invasive approach to diagnosis, prognosis and prediction of diseases. Consequently, the study of the hu-
man urinary proteome has increased dramatically over the last 10 years, with many studies being published. This review focuses on urinary protein 
biomarkers that have shown potential, in initial studies, for diseases affecting the urogenital tract, specifically chronic kidney disease and prostate 
cancer, as well as other non-urogenital pathologies such as breast cancer, diabetes, atherosclerosis and osteoarthritis. PubMed was searched for 
peer-reviewed literature on the subject, published in the last 10 years. The keywords used were “urine, biomarker, protein, and/or prostate cancer/
breast cancer/chronic kidney disease/diabetes/atherosclerosis/osteoarthritis”. Original studies on the subject, as well as a small number of reviews, 
were analysed including the strengths and weaknesses, and we summarized the performance of biomarkers that demonstrated potential. One of 
the biggest challenges found is that biomarkers are often shared by several pathologies so are not specific to one disease. Therefore, the trend is 
shifting towards implementing a panel of biomarkers, which may increase specificity. Although there have been many advances in urinary proteo-
mics, these have not resulted in similar advancements in clinical practice due to high costs and the lack of large data sets. In order to translate these 
potential biomarkers to clinical practice, vigorous validation is needed, with input from industry or large collaborative studies.
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Introduction
Proteomics is the study of proteins expressed by 
an organism or cellular system (proteome), in or-
der to understand cellular processes. This is an 
area that has been widely explored in the past 
decade and during this time highly sensitive tech-
niques have been developed for analyzing the 
proteome of biological samples such as cells, tis-
sues and body fluids (1,2). Progress that has been 
made in new technologies, has led to the discov-
ery of many potential biomarkers. These mole-
cules are measurable indicators of a biological 
state (3), be it normal or abnormal, and therefore 
can be used in a clinical setting in disease diagno-
sis and management. 
Biomarkers can be of varied chemical nature, be 
they genetic (DNA and RNA), proteins, secondary 
metabolites or carbohydrates. Although genetic 
and protein biomarkers are the most studied, the 
latter have gained recognition due to the close 
correlation that exists between the proteome and 
the biological activity of the cell or system. Pro-
teins are directly responsible for cell function, thus 
abnormal protein expression is an indication of 
cellular disruption due to a pathological condition 
(4).
Biomarkers can be found in different biological 
samples. Blood has been the most widely studied 
source of biomarkers to date, as it is in contact 
with all the cells in the body. However, proteomic 
analysis of blood samples poses certain disadvan-
tages. During sample collection proteases are of-
ten activated, which generates a range of proteo-
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lytic products, thus introducing variability to the 
sample (5). Furthermore, blood contains 20 high 
abundance proteins which correspond to 99% of 
the proteins in the sample (6,7); these high abun-
dance proteins mask other less abundant, poten-
tially interesting proteins. Due to this, urine has 
roused great interest in recent years. Urine is an ul-
tra filtration of the blood in the body and is very 
stable compared to blood (8,9). It is easy to process 
in the lab, large amounts can be obtained, and its 
collection is simple and non-invasive causing mini-
mal stress to patients (10). The impact of urinary 
biomarkers in a clinical setting lies in these advan-
tages, as they could provide valuable information 
without the need for costly and invasive screen-
ing/diagnostic/monitoring procedures for the pa-
tient. This could also translate into improved, early 
screening programs, in order to reduce illness and 
death, thus diminishing the burden on the health-
care system. The main disadvantage of urine is the 
variation in protein concentration due to differ-
ences in fluid consumption during the day; how-
ever, this can be countered by normalizing with 
creatinine (7). 
The Human Proteome Organization (HUPO) ap-
proved the Human Kidney and Urine Proteome 
Project in October 2007 as one of the HUPO-spon-
sored scientific initiatives, in which more than 150 
participating scientists collect and publicly share 
proteomics data on urine. Approximately 1500 
proteins have been shown to constitute the uri-
nary proteome (11), of which large proportions are 
extra cellular proteins, plasma membrane pro-
teins, and lysosomal proteins. Several studies have 
indicated that under physiological conditions ap-
proximately 30% of the proteins in normal human 
urine are plasma proteins, while the other 70% are 
proteins derived from the kidney and genitouri-
nary tract (12-15). Therefore, as expected, urine is 
an interesting source of biomarkers for monitoring 
the health of kidneys and genitourinary organs 
(such as the prostate), which secrete proteins into 
the urine (16). However, protein biomarkers have 
also been identified in urine for other types of dis-
orders, such as different types of cancer, metabolic 
diseases, and even immunological disorders 
(9,17,18). 
A search of the literature reveals many biomarker 
candidates identified in urine by different strate-
gies; however, few have been implemented in a 
clinical setting. One of the biggest challenges is 
that biomarkers are often shared by several pa-
thologies so are not specific to one disease, as evi-
denced in this review. Rather than a single urinary 
protein biomarker, a panel of biomarkers may be 
required to achieve the overall high level of speci-
ficity needed. When seemingly contradictory re-
sults are seen in this light, they may be understood 
as complementary. The aim of this review is to pre-
sent an overview of some of the recent protein bi-
omarkers found in urine, and their potential use in 
the diagnosis of different pathologies involving 
the kidney and urinary tract, as well as of cancer, 
metabolic and inflammatory diseases. Integrating 
information from different studies will allow for 
disease-specificity of biomarker candidates to be 
better evaluated, by comparing studies across var-
ious diseases. In the first part of this review, we 
summarize a few of the potential protein biomark-
ers recently detected in urine for chronic kidney 
disease, glomerulonephritis and kidney transplant 
rejection. This is followed by advances in urinary 
protein biomarkers for prostate and breast cancer, 
as well as diabetes, atherosclerosis and osteoar-
thritis. In addition, we summarized the biomarkers 
described for each condition, including clinical im-
portance of the biomarkers, references of main 
studies, sensitivity and specificity, types of meth-
ods used in the studies and sample size (table 1).
Materials and methods 
The keywords “urine, protein, biomarkers” used in 
a general PubMed search yielded over 10,000 pa-
pers on the subject. Due to the wide range of pub-
lications available, it was necessary to concentrate 
on a few important diseases for which urinary pro-
tein biomarkers have been proposed. We selected 
a couple of diseases affecting the urogenital tract, 
specifically chronic kidney disease and prostate 
cancer, as well as a few non-urogenital patholo-
gies, such as breast cancer, diabetes, atherosclero-
sis and osteoarthritis. A more limited PubMed 
search using keywords “urine, biomarker, protein, 
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Disease Biomarkers Clinical importance Reference
Sensitivity and 
specificity Method
Sample 
size
CK
D
Collagen fragments, A1AT, albumin, 
haemoglobin α chain, and fibrinogen 
α chain, uromodulin, sodium/
potassium-transporting ATPase 
γ chain, membrane-associated 
progesterone receptor component 1
Diagnosis (19)
Training set:  
Sensitivity 98.7% 
Specificity 100% 
Test set (Validation) 
Sensitivity 85.5% 
Specificity  100%
CE-MS
Training 
set: 3600 
Test set: 
144
Ig
A
N
The identity of the peptides in 
this panel of biomarkers was not 
established
Diagnosis (24)
Discrimination of IgAN 
- controls:  
Sensitivity 100% 
Specificity  90% 
Discrimination  
IgAN - Membranous 
nephropathy: 
Sensitivity 77% 
Specificity 100%
CE-MS 115
Uromodulin, α1-antitrypsin (A1AT) 
and β2-microglobulin peptides Diagnosis (25) Not given
Magnetic bead 
technology and 
MALDI-TOF MS
33
NGAL Diagnosis (28) Sensitivity 90.2% Specificity 67.9% ELISA and IHC 70
Pr
os
ta
te
 c
an
ce
r
Annexin A3 Diagnosis (36)
Area under the ROC 
curve of 0.82 for 
combined Annexin A3/
PSA
Western Blot 591
Uromodulin and semenogelin Diagnosis (37) Sensitivity 71.2%  Specificity 67.4% MALDI-TOF 407
Sodium/potassium-transporting 
ATPase γ, Collagen α fragments (I and 
III), Psoriasis susceptibility 1 candidate 
gene 2 protein,  hepatocellular 
carcinoma associated protein TB6, 
histone H2B, osteopontin, polymeric 
Ig receptor, transmembrane 
secretory component, prostatic acid 
phosphatase, fibrinogen α chain 
precursor, and semenogelin 1
Diagnosis (9) Sensitivity 91% Specificity 69% CE-MS 86
EN2
Diagnosis 
and 
prognosis
(40-42)
(40) - 66% sensitivity 
and 88.2% specificity 
(41) - 66.7% sensitivity 
and 89.3% specificity
RT-PCR, IHC and 
ELISA
(40) - 184 
(41) - 413 
(42) - 125
Br
ea
st
 
ca
nc
er MMP-9 and ADAM-12
Risk 
stratification (51)
Area under the curve of 
0.914 and 0.950 IHC 148
NGAL/Lcn2 Diagnosis (59) Likelihood ratio test = 5.0, P = 0.025 ELISA 20
Table 1. Summary of biomarkers described in this review.
and/or prostate cancer / breast cancer / chronic 
kidney disease / diabetes / atherosclerosis / osteo-
arthritis “, yielded 2,349 papers overall. The search 
was limited to papers published in English in the 
past 10 years, with abstract and full text available. 
The titles and abstracts were reviewed and the 
most relevant publications were selected. Due to 
the broad character of the review subject, we fo-
cused mainly on novel studies with larger human 
cohorts.
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Disease Biomarkers Clinical importance Reference
Sensitivity and 
specificity Method
Sample 
size
D
ia
be
te
s
Collagen fragments α1 (I 
and III), fibrinogen, A1AT, 
membrane-associated progesterone 
receptor component 1 and 
uromodulin
Diagnosis (18)
Distinguish DM - 
controls: 94% accuracy 
Distinguish T1D - T2D: 
88% accuracy
CE-MS 902
Gelsolin, antithrombin III, ephrin 
type-B receptor 4, vitamin 
K-dependent protein Z
Diagnosis 
and 
progression
(68) Not given LC-MS/MS 35
Uromodulin, apolipoprotein 
A-I, apolipoprotein E, α2-thiol 
proteinase inhibitor, human 
complement regulatory protein 
CD59, α1-microglobulin, zinc-α2 
glycoprotein, α-1B glycoprotein, 
retinol-binding protein 4
Progression (38) Not given 2DE, LC-MS/MS, MALDI-TOF-MS Not given
A
th
er
os
cl
er
os
is
Collagen α1 fragments (types I and III) Diagnosis (71)
Sensitivity 81%, 
specificity 92% and 
84% accuracy
CE-MS 67
Collagen α1 fragments (types 
I and III), A1AT, granin-like 
neuroendocrine peptide precursor, 
membrane-associated progesterone 
receptor component 1, sodium/
potassium-transporting ATPase 
gamma chain, fibrinogen- α chain
Diagnosis 
and 
response to 
treatment
(74) Area under the ROC curve 87% CE-MS 623
O
st
eo
ar
th
ri
ti
s
Collagen type II fragments Diagnosis (78, 79) Not given LC-MS/MS Not given
Fibulin-3, β-actin, α1-microglobulin, 
apoptosis-inducing factor-2, 
Zn-α2-glycoprotein precursor, 
serpin β1 and β3, mannan binding 
lectin serine protease-2 precursor, 
kinninogen-1 precursor and A1AT.
Diagnosis (80)
Fib3-1: Specificity 77.1% 
and sensitivity 68.4%  
Fib3-2: Specificity  
85.7% and sensitivity 
74.6%
2D-DIGE and MS 15
CKD - chronic kidney disease; A1AT - α1-antitrypsin; CE-MS - capillary electrophoresis-mass spectrometry; IgAN - IgA 
nephropathy; MALDI TOF MS - matrix-assisted laser desorption-ionization time-of-flight mass spectrometry; NGAL - neutrophil 
gelatinase-associated lipocalin; ELISA - enzyme-linked immunosorbent assay; IHC - immunohistochemistry; EN2 - engrailed-2; 
RT-PCR - real time polymorphisms chain reaction; MMP - matrix metalloproteinase; ADAM - a disintegrin and metalloproteinase; 
LCN2 - lipocalin-2; LC-MS/MS - liquid chromatography-tandem mass spectrometry; 2DE - two-dimensional gel electrophoresis; 
2D-DIGE - two-dimensional difference gel electrophoresis.
Kidney disease
Chronic kidney disease (CKD) is characterized by 
the progressive loss of renal function. This disease 
may take decades to progress and can eventually 
lead to kidney failure, requiring dialysis or a kidney 
transplant for survival (19). The initial diagnostic 
tests for CKD include measuring proteinuria and 
serum creatinine; however, it has been shown that 
these diagnostic aids are not sensitive enough in 
the early stages of the disease or specific to the 
variations between individuals (19-21).
Many potential protein biomarkers for CKD have 
been suggested, including a panel of 273 CKD 
specific peptides reported by Good and col-
leagues (19) in 2010 for the early diagnosis of the 
disease. In this study urine samples were collected 
from 3,600 individuals in over 20 clinical centres 
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around America, Europe and Australia, and were 
analyzed using capillary electrophoresis-mass 
spectrometry (CE-MS). This biomarker pattern of 
273 peptides was able to distinguish between 
healthy individuals and those with CKD with a 
specificity of 100% and a sensitivity value of 98.7%. 
This model was then validated in an independent 
blinded cohort of 144 individuals with sensitivity 
results of 85.5% and 100% specificity. These pro-
teins differentially expressed in urine of patients 
with CKD included different collagen fragments, 
serum proteins like α1-antitrypsin (A1AT), albumin, 
haemoglobin α chain, and fibrinogen α chain, as 
well as kidney-specific proteins such as uromodu-
lin, sodium/potassium-transporting ATPase γ 
chain, and membrane-associated progesterone 
receptor component 1. Despite the high specificity 
achieved it must be noted that the training set 
used in this study included patients with various 
biopsy-proven kidney diseases, such as IgA ne-
phropathy, diabetic nephropathy, vasculitis, lupus 
and glomerulonephritis; so this panel of biomark-
ers is not specific for one disease, but for kidney 
disease in general.
IgA nephropathy
Several conditions have been associated with the 
onset of CKD, including diabetic nephropathy, hy-
pertension and glomerulonephritis (22). Kidney 
damage observed in glomerulonephritis is charac-
terized by changes in glomerular permeability and 
structure. Selective filtration mainly occurs in the 
glomerular basement membrane where proteins 
are excluded based on their size and charge. How-
ever, in glomerulonephritis permeability is altered 
leading to serum proteins leaking into urine. Dif-
ferent types of glomerulonephritis have been clin-
ically described, the most common type being IgA 
nephropathy (IgAN). IgAN leads to end stage renal 
disease within 25 years of the manifestation of the 
disease, in approximately 25% to 30% of cases (23). 
The current clinical practice for confirming IgAN 
diagnosis is renal biopsy. This has driven research-
ers around the world to work on developing non-
invasive diagnostic tools for the early detection of 
IgAN.
In a study published in 2005 (24), urine samples 
from 45 patients with IgAN, 13 patients with mem-
branous nephropathy and 57 healthy controls 
were screened using CE-MS. This study revealed 
that the urinary proteome of patients with IgAN 
was significantly different and could be success-
fully used to distinguish those patients with IgAN 
from the other two study groups, even when pro-
tein excretion into urine was within the normal 
range. Another interesting finding was that as pa-
tients with IgAN underwent treatment their uri-
nary proteome changed adopting a pattern simi-
lar to that displayed by the control subjects. From 
this study we are able to conclude that IgAN pa-
tients exhibit a specific urinary proteomic profile 
that can differentiate them from healthy individu-
als and from patients with other renal diseases, as 
well as allowing for treatment effectiveness to be 
monitored; however, the identity of the peptides 
in this panel of biomarkers was not established. 
In a recent study (25), 55 peptides that differenti-
ated between IgAN patients and healthy subjects 
were isolated from blood and urine samples taken 
from 33 individuals (19 with biopsy-proven IgAN 
and 14 controls). Sensitivity and specificity data 
were not given. Sixteen of these 55 peptides were 
identified in urine and corresponded to uromodu-
lin, α1-antitrypsin and β2-microglobulin peptides. 
These peptides were also correlated with poor his-
tological lesions typical of patients with IgAN, par-
ticularly tubulointerstitial damage and segmental 
glomerulosclerosis. However, it seems that the in-
creased expression of A1AT is due mostly to the in-
flammatory process rather than being a specific 
response to the disease, so is therefore not a spe-
cific biomarker for IgAN. Similarly, uromodulin has 
been implicated in other renal diseases so is also 
not a specific biomarker for IgAN (26,27). 
Tubulointerstitial injury plays an important role in 
the development of IgAN and is typically diag-
nosed by measuring the levels of N-acetyl-β-D-
glucosaminidase (NAG) in urine or in tissue. How-
ever, NAG is a lysosomal enzyme that is increased 
when there is damage to the renal tubules, so it 
can also be found at higher levels in patients suf-
fering from diseases such as nephrotic syndrome, 
glomerulonephritis and diabetic nephropathy. 
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Since NAG is not a specific biomarker of IgAN it 
was necessary to search for more specific biomark-
ers of the disease and neutrophil gelatinase-asso-
ciated lipocalin (NGAL) was suggested. Ding and 
colleagues (28) found that urinary levels of NGAL 
were significantly higher in patients with IgAN 
compared to healthy controls, even when in-
creased NAG levels could not yet be detected. 
NGAL is more specific (67.9%) and sensitive (90.2%) 
for IgAN detection compared to NAG (82.4% sensi-
tivity and 60.5% specificity) suggesting that uri-
nary NGAL is a superior biomarker of early tubu-
lointerstitial injury in IgAN. However, this corre-
sponds to a preliminary study with 70 patients and 
needs to be validated with a larger cohort of pa-
tients.
Cancer
Cancer is a serious public health concern world-
wide. Each year more than 12 million people are 
diagnosed with some type of cancer and approxi-
mately 7 million people die from cancer each year 
(29). The highly heterogeneous nature of cancer 
provides a real challenge for clinical disease man-
agement; clinical progression is often difficult to 
predict and treatment is therefore not as effective 
as it should be. Consequently, the use of biomark-
ers as an aid for early diagnosis and monitoring 
progression and treatment effectiveness has been 
extensively studied.
Prostate cancer
Prostate cancer is the second most prevalent can-
cer in men worldwide after lung cancer. The Inter-
national Agency for Research on Cancer in its lat-
est report (29) estimated a global incidence of 
899,000 new cases of prostate cancer per year and 
an annual mortality rate of 258,000 men due to 
this disease. 
The classic diagnostic tools for prostate cancer de-
tection are the measurement of prostate specific 
antigen (PSA) in serum, digital rectal examination 
and imaging techniques. The least invasive of 
these is the measurement of PSA levels in the 
blood, which is a protein naturally produced by 
the prostate that helps keep the semen in its liquid 
form. PSA levels are elevated as a result of prostate 
cancer; however, there are other factors such as 
benign prostatic hyperplasia, age and sexual activ-
ity that also raise PSA levels, so this test produces 
many false positives (30). There are also some pros-
tate cancers that exhibit normal PSA levels and 
therefore are not detected in time (31), which leads 
to more aggressive treatment later on. In the last 
few years there has been great progress into alter-
nate ways of using the PSA test with better perfor-
mance. The Prostate Health Index (PHI) is a new 
formula that combines all three forms of PSA (total 
PSA, free PSA and proPSA) into a single score that 
can be used to aid in diagnosis and management. 
A recent study has shown (32) that proPSA and PHI 
can discriminate between patients with prostate 
cancer and those with benign prostatic hyperpla-
sia or chronic histological prostatic inflammation, 
thus reducing the need for unnecessary biopsies 
by 27%. However, PHI is not effective for stratifica-
tion of patients.
Advances are also being made on potential uri-
nary biomarkers for prostate cancer. Annexin A3 is 
a calcium-binding protein that plays a role in the 
regulation of cellular growth and in signal trans-
duction pathways, and as such has been shown to 
have important roles in tumour development, me-
tastasis and drug resistance (33). A large study us-
ing urine samples from 591 patients (34) reported 
Annexin A3 as a novel urine-based biomarker for 
early prostate cancer detection when used in con-
junction with PSA. The accuracy of the combined 
annexin A3/PSA test was superior to PSA alone 
(area under the ROC curve of 0.82 versus 0.68). 
Using MALDI-TOF (matrix-assisted laser desorp-
tion-ionization time-of-flight) another large study 
(35) of 407 urine samples identified uromodulin 
and semenogelin as protein biomarkers of interest 
that could distinguish between prostate cancer 
and benign prostatic hyperplasia with 71.2% sensi-
tivity and 67.4% specificity. Semenogelin, a semi-
nal vesicle derived protein found in seminal fluid, 
was over expressed in patients with prostate can-
cer; while uromodulin, an abundant protein in 
normal human urine, was down regulated in these 
patients. Despite the large dataset in this study, 
the sensitivity and specificity of these proteins was 
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quite low, hence they are not prime candidates to 
be used on their own. Changes in uromodulin 
have also been detected in diabetes (18,36) and 
chronic kidney disease (19); and it has been ac-
cepted by the US Food and Drug Administration, 
European Medicines Agency, and Pharmaceuticals 
and Medical Devices Agency, as a urinary biomark-
er for detecting drug-induced kidney injury during 
preclinical toxicological testing (37). 
In 2008, Theodorescu and colleagues (9) used CE-
MS to identify and validate 12 biomarkers from 
first void urine that were able to identify patients 
with prostate cancer with 91% sensitivity and 69% 
specificity. The identified biomarkers  were sodi-
um/potassium-transporting ATPase γ, collagen α-1 
(III), collagen α-1(I), psoriasis susceptibility 1 candi-
date gene 2 protein, hepatocellular carcinoma as-
sociated protein TB6, histone H2B, osteopontin, 
polymeric Ig receptor, transmembrane secretory 
component, prostatic acid phosphatase, fibrino-
gen α chain precursor, and semenogelin 1, most of 
which were found to be down-regulated in pa-
tients with prostate cancer. This study supports 
the use of a panel of biomarkers for disease diag-
nosis rather than a stand-alone biomarker.
Recently, engrailed-2 (EN2), a homeobox protein 
involved in the development of the normal pros-
tate gland, was found to detect prostate cancer in 
urine with 66.7% sensitivity and 89.3% specificity 
using an ELISA-based assay (38,39). This protein 
was found in urine of prostate cancer patients but 
was no longer detectable after prostatectomy in 
the same patients, nor in healthy controls, indicat-
ing a diagnostic potential for EN2. The high pre-
dictive value of urinary EN2 raises the possibility 
that it could be used alongside PSA in the diagno-
sis of prostate cancer, in order to increase sensitiv-
ity and specificity in diagnosis, thus picking up 
those cancers that would go undetected, and also 
reducing the number of false positives thus avoid-
ing unnecessary prostate biopsies. In a later study 
by the same research group (40), a positive correla-
tion was shown between urinary levels of EN2 and 
prostate cancer volume, marking it as a useful bio-
marker not only for prostate cancer diagnosis but 
also for risk stratification. To date this is the first bi-
omarker of prostate cancer that correlates with the 
amount of cancer present, and could potentially 
aid in making clinical decisions regarding disease 
management (treatment vs. surveillance). Current-
ly none of these urinary protein biomarkers have 
been introduced into clinical practice.
Breast cancer
Prostate cancer is a urogenital disease, so it is logi-
cal to think that biomarkers for this disease can 
easily be found in urine, however other non-uro-
genital cancers also exhibit changes in the urinary 
proteomic profile; an example of this is breast can-
cer. Breast cancer is by far the most frequent can-
cer among women, with an estimated 1.38 million 
new cancer cases per year and an annual mortality 
rate of 458,000 women worldwide (29). If breast 
cancer is detected during its earlier stages, the 
5-year survival rate may be as high as 93% (41), 
making early detection essential for favourable 
prognosis. Current guidelines for the early detec-
tion of breast cancer include mammography and 
clinical breast examination. However, not all cases 
of breast cancer are detected by a mammogram, 
and many women experience false alarms. Results 
from several randomized screening trials (42,43) 
suggest that mammography reduces breast can-
cer mortality rate by 15% to 20%. Tumour markers 
currently in use in the evaluation of breast cancer, 
as recommended by the National Academy of 
Clinical Biochemistry (NACB) (44), include estrogen 
and progesterone receptors, human epidermal 
growth factor receptor-2, urokinase plasminogen 
activator/plasminogen activator inhibitor 1 and 
cancer antigen 15-3. These are useful for predict-
ing response to therapy, but show little potential 
for early detection (45). In recent years, several 
studies have reported urinary biomarkers for 
breast cancer detection (46); among those report-
ed are the matrix metalloproteinase’s (MMPs) and 
ADAMS (A Disintegrin And Metalloproteinase). 
These proteins are zinc proteases that degrade the 
components of the extra cellular matrix, and as 
such are involved in the process of tumour pro-
gression, from angiogenesis and cell migration, to 
remodelling of the tumour microenvironment, in-
vasion, and metastasis (47,48). 
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A study of 148 women (49) showed that women 
with high levels of MMP-9 and ADAM-12 in urine 
were 5 times more likely to develop atypical hy-
perplasia and 13 times more likely to develop lob-
ular carcinoma in situ, which are precursors of can-
cer. Therefore, it might be concluded that these 
biomarkers not only act as indicators of the pres-
ence of breast cancer, but also as high-risk predic-
tors. It is reported that ADAM-12, expressed by 
cancer cells, accelerates breast cancer progression 
by inducing apoptosis of stromal cells (50) and by 
degrading several extra cellular matrix compo-
nents such as collagen type IV and fibronectin (51).
In contrast, a recent study (52) of 50 breast cancer 
patients and 46 matched controls did not find a 
significant difference in the urinary ADAM-12 lev-
els between these two study groups, but did re-
port an increase following surgery (P < 0.001). This 
could mean that the increase in ADAM-12 is due to 
trauma and inflammation in the tissue, rather than 
specifically due to breast cancer. This is supported 
by other studies that have reported ADAM-12 over 
expression in other cancer types, such as brain, co-
lon, gastric and lung cancer (53-55).
Another MMP related protein of interest in breast 
cancer is NGAL. NGAL is part of the matrix metal-
loproteinase-9 (MMP-9) complex and has a role in 
protecting MMP-9 from auto degradation, thereby 
protecting its enzymatic activity (56). A study of 20 
urine samples (57) showed that NGAL levels were 
significantly higher in samples from metastatic 
breast cancer patients compared with healthy 
women. These results were also consistent with 
immunohistochemistry results of breast tissue as 
well as in vitro and animal studies, leading to the 
conclusion that NGAL levels are associated with 
poor prognosis, high proliferation and decreased 
survival. Recent evidence suggests, however, that 
increased expression of NGAL may also occur in 
other cancer types, such as bladder, colorectal, liv-
er, lung, ovarian, and pancreatic cancer (58), as well 
as in renal failure (59). 
Despite the number of published studies on breast 
cancer biomarkers, yet there is no validated uri-
nary biomarker available for use in routine clinical 
practice, therefore breast cancer detection and 
monitoring remains dependent mostly on invasive 
procedures.
Metabolic and inflammatory diseases
The search for biomarkers in urine has also been 
extended to metabolic and inflammatory diseas-
es, which have high morbidity rates, such as diabe-
tes, atherosclerosis and osteoarthritis.
Diabetes
Diabetes mellitus (DM) is a complex disease char-
acterized by the impaired metabolism of glucose, 
its main symptom being the increase in blood glu-
cose levels (hyperglycaemia). With time, these al-
terations cause secondary cellular dysfunctions 
and vascular damage including diabetic nephrop-
athy. The disease has been classified into two main 
types. Type 1 diabetes (T1D) is associated with de-
struction of insulin-producing β-cells in the pan-
creas, typically by an autoimmune mechanism, 
leading to insufficient insulin production. Type 2 
diabetes (T2D) on the other hand, is caused by in-
sulin resistance, which is the inability of cells to re-
spond adequately to insulin, and is often associat-
ed with obesity.
Both types of diabetes are diagnosed and moni-
tored by measuring fasting plasma glucose con-
centration, haemoglobin A1C levels and with the 
oral glucose tolerance test (60). According to the 
International Diabetes Federation (61), T2D fre-
quently goes undetected leading to further com-
plications. In countries such as the US approxi-
mately 30% of cases are not diagnosed, while in 
African countries this number can be as high as 
90%. For those that are diagnosed, on average a 
diagnosis is reached between 4 and 7 years after 
the onset of the disease (62). For this reason, differ-
ent research groups have focused on finding early 
onset biomarkers. 
An early study (63) evaluated the urinary pro-
teome of 305 individuals, using CE-MS, and identi-
fied a panel of 261 biomarkers which could distin-
guish between diabetic patients and healthy con-
trols with 89% sensitivity and 91% specificity. 
These results were later validated in a larger study 
Biochemia Medica 2015;25(1):22–35  http://dx.doi.org/10.11613/BM.2015.003 
30
Pedroza-Díaz J, Röthlisberger S. Advances in urinary protein biomarkers
(18) of 587 diabetic patients (299 T1D and 288 T2D) 
and 315 healthy individuals, with similar sensitivity 
and specificity results. The differences in T1D and 
T2D urine samples were also evaluated and a pan-
el of 131 potential biomarkers was proposed. The 
majority of the identified biomarkers were frag-
ments of collagen α-1 (I and III), fibrinogen, α1-
antitrypsin (A1AT), membrane-associated proges-
terone receptor component 1 and uromodulin. 
One of the most predominant changes in the uri-
nary proteome of the diabetic patients was a sig-
nificant reduction in collagen fragments com-
pared to controls. This shift was more noticeable 
in patients with T2D compared to those with T1D, 
indicating differences in extra cellular matrix re-
modelling. Another interesting find was that al-
though A1AT, an acute phase protein and physio-
logical inhibitor of serine proteases, was detected 
in low levels in plasma samples of diabetic pa-
tients, in urine it was significantly increased, which 
suggests a possible increase in degradation and 
clearance in the kidneys (18,64). The increased 
degradation of A1AT facilitates the conversion of fi-
brinogen to fibrin by thrombin, leading to a higher 
risk of atherothrombotic disorders in patients with 
diabetes (65).
A study conducted in 2012 (66) with 15 T1D pa-
tients, with and without complications, such as 
retinopathy and nephropathy, reported gelsolin 
and antithrombin III as promising urinary biomark-
ers for the early diagnosis of T1D; while ephrin 
type-B receptor 4 and vitamin K-dependent pro-
tein Z could be used to predict T1D progression 
(retinopathy and nephropathy). These proteins are 
associated to micro vascular complications that 
are so common with T1D. The limitation of this 
study however, is the small dataset used; so prior 
to drawing any conclusions it is necessary to vali-
date these results in a larger dataset.
Another study (36) identified urinary proteins cor-
related with the progression and complications of 
T1D. Samples were taken from diabetic patients 
classified in two groups according to their albumi-
nuria levels (norm-albuminuria and micro-albumi-
nuria) and compared with healthy individuals us-
ing high-resolution two-dimensional gel electro-
phoresis (2DE), MALDI-TOF-MS and liquid chroma-
tography– tandem mass spectrometry (LC-MS/MS) 
analysis. Uromodulin, apolipoprotein A-I, apolipo-
protein E, α2-thiol proteinase inhibitor, and human 
complement regulatory protein CD59 were found 
in lower levels in diabetic patients with micro-al-
buminuria, while proteins such as α1-microglobulin, 
zinc-α2 glycoprotein, α-1B glycoprotein, and retinol-
binding protein 4 were highly expressed in the 
same study group. These proteins are associated 
with microalbuminuria and therefore could be use-
ful for monitoring the progression of T1D.
Changes in the above biomarkers are most likely 
due to renal complications rather than to diabetes 
specifically. This is supported by studies which 
have shown that urinary collagen and fibrinogen 
fragments, A1AT, uromodulin, and membrane-as-
sociated progesterone receptor component 1 are 
also observed in kidney disease (19). Gelsolin (67), 
A1AT and apolipoprotein E (68) have been detect-
ed in urine samples of patients with bladder can-
cer; and uromodulin (also known as Tamm-Hors-
fall urinary glycoprotein) has been accepted by the 
US Food and Drug Administration, European Med-
icines Agency, and Pharmaceuticals and Medical 
Devices Agency, as a urinary biomarker for detect-
ing drug-induced kidney injury during preclinical 
toxicological testing (37).
Atherosclerosis
Atherosclerosis is a chronic, inflammatory disease 
of the arterial wall that underlies many of the com-
mon causes of cardiovascular morbidity and mor-
tality, including myocardial infarction, stroke and 
peripheral vascular disease. Some people who 
have atherosclerosis have no signs or symptoms. 
They may not be diagnosed until after a heart at-
tack or stroke, therefore early detection is crucial.
Several studies have evaluated biomarkers for the 
early detection of atherosclerosis. In one of these 
studies (69), plasma and urine proteomes were 
evaluated in 67 elderly patients with and without 
coronary artery disease (CAD), who presented typ-
ical angina symptoms as well as the classic risk fac-
tors for atherosclerosis (hyperlipidaemia, diabetes, 
history of smoking, familial history of CAD and hy-
pertension). With a combination of 17 urinary pol-
ypeptides it was possible to discriminate between 
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CAD positive and negative patients with 81% sen-
sitivity, 92% specificity and 84% accuracy. It is in-
teresting to note that this was not possible using 
plasma proteins. Some of these urinary proteins 
were identified as collagen α1 fragments (types I 
and III), and were later isolated from atherosclerot-
ic plaques in the aorta of patients with this disease. 
Type III collagen fragments were also detected in 
urine of atherosclerotic mice (ApoE -/-) (70) indicat-
ing ECM remodelling in this animal model. Type I 
and type III collagens are among the most pre-
dominant proteins of the arterial extra cellular ma-
trix and are important for arterial integrity and 
plaque stability. Degradation of collagen by matrix 
metalloproteinase’s (MMPs) is one of the main 
mechanisms of plaque rupture (71), therefore, it is 
logical to think that these fragments may be pre-
sent in urine of patients with atherosclerosis. How-
ever, collagen α1 fragments (types I and III) have 
also been detected in urine of patients with diabe-
tes (18), chronic kidney disease (19) and prostate 
cancer (9). Therefore, they are not indicative of a 
specific disease, but rather of a pathological state 
in general.
A large study of 623 patients with and without cor-
onary artery disease (72) reported a panel of 238 
proteins which were specific to patients with CAD 
(area under the ROC curve 87%). The panel of bio-
markers included fragments of α1-antitrypsin, col-
lagen α1 fragments (types I and III), granin-like 
neuroendocrine peptide precursor, membrane-as-
sociated progesterone receptor component 1, so-
dium/potassium-transporting ATPase gamma 
chain and fibrinogen- α chain. Biomarker expres-
sion also changed after long term treatment with 
irbesartan, returning to more normal levels. An-
other study published a couple of years later (73) 
aimed to find proteins involved in atherogenesis 
and therefore reflect the early stages of athero-
sclerosis, using the gold standard animal model of 
atherosclerosis, namely the ApoE (-/-) mice. The 
urinary proteomic profiles of ApoE (-/-) mice on 
control and high-fat diets were compared to wild-
type mice on high-fat diet using MS. The results 
revealed 16 urinary polypeptides specific to ApoE 
(-/-) mice on the high-fat diet. These included frag-
ments of α1-antitrypsin, epidermal growth factor 
(EGF), kidney androgen-regulated protein, and 
collagen. In a blind study the researchers were 
able to identify the atherosclerotic mice, with 90% 
sensitivity and 100% specificity, by detecting these 
protein biomarkers in urine. It is noteworthy that 
α1-antitrypsin, EGF and collagen type I were found 
not only to be highly expressed in atherosclerotic 
plaques of these mice but were also present in 
high concentrations in the urine of human pa-
tients with this disease. Therefore, it may also be 
possible to identify human patients with athero-
sclerosis using this panel of biomarkers.
These studies reflect the growing trend towards 
the search for a panel of biomarkers, which can 
yield greater sensitivity and specificity results than 
a single protein. Promising urinary protein bio-
markers have been reported for cardiovascular 
disease, although to date none of these have been 
implemented in clinical practice. 
Osteoarthritis
Osteoarthritis (OA) is a chronic, slow progressing 
condition characterized by the breakdown of car-
tilage in the joints. A diagnosis of OA is currently 
made based on medical history and clinical exami-
nation, and confirmed by measuring the joint 
space width using X-ray. However, with these diag-
nostic methods, it is impossible to detect the early 
metabolic changes that occur prior to the visible 
structural changes in the joint tissues; which raises 
the need for molecular biomarkers of OA.
Degradation of type II collagen by proteolytic en-
zymes secreted by chondrocytes and synovio-
cytes is a central feature of OA (74). Evidence sug-
gests (75) that this degradation of the extra cellu-
lar matrix is mainly mediated by MMPs. Using LC-
MS/MS, collagen type II peptides were isolated 
from urine of patients with the disease (76); frag-
ments which were found to be mainly produced 
by MMP-13. This was later clinically validated (77) 
and the assay was shown to differentiate between 
patients with symptomatic OA and healthy indi-
viduals; therefore, type II collagen peptides are 
candidate biomarkers for MMP-13 activity in carti-
lage and the consequent pathogenesis of OA.
Another study (78) that compared 10 urine sam-
ples from women with severe OA and 5 healthy 
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controls, using 2D-DIGE and mass spectrometry, 
revealed 13 proteins of interest that were signifi-
cantly over expressed or under expressed in urine 
of OA patients compared to healthy controls. 
These proteins included β-actin, α1-microglobulin, 
apoptosis-inducing factor-2, Zn-α2-glycoprotein 
precursor, serpin β1 and β3, mannan binding lec-
tin serine protease-2 precursor, kinninogen-1 pre-
cursor and α1-antitrypsin; however, this study fo-
cused on two specific sequences of fibulin-3 (Fib3-
1 and Fib3-2) which were identified from the 2 
most increased spots in the urinary proteome of 
the OA patients. Fibulin-3 is an extra cellular matrix 
protein found to be involved in the pathogenesis 
of OA via its association with Tissue Inhibitor of 
Metalloproteinase’s 3 (TIMP3) (79,80).
A global initiative has been put in place by the Os-
teoarthritis Research Society International (OARSI) 
(81) to assess 12 biochemical markers of osteoar-
thritis in serum and urine, examine how well they 
correlate with clinical outcome, and establish their 
predictive validity using a large data set. These bi-
ochemical markers include hyaluronan, COMP, col-
lagen I and II epitopes, aggrecan and MMP-3. This 
initiative should accelerate biomarker discovery 
and development for OA, allowing a preventative 
approach for managing the disease and a better 
use of the existing therapies.
Concluding remarks
Current diagnostic biomarkers are suboptimal and 
of poor utility for low grade disease and surveil-
lance. To date many potential urinary protein bio-
markers have been explored for diseases such as 
prostate cancer, breast cancer, diabetes, osteoar-
thritis and kidney disease. Some of these biomark-
ers are detected early on in the asymptomatic 
stage of the disease and are useful for risk stratifi-
cation or for early diagnosis, such as MMP-9 and 
ADAM-12 for breast cancer and Annexin A3 for 
prostate cancer. Other biomarkers, such as ephrin 
type-B receptor 4 and vitamin K-dependent pro-
tein Z in type 1 diabetes, are used in the later stag-
es of the disease, but are not useful for the initial 
diagnosis. One of the biggest challenges is that bi-
omarkers are often shared by several pathologies, 
so are not specific to one disease. It is not sufficient 
to compare the urinary proteomes of patients with 
a certain disease and healthy individuals. The key 
to identifying promising biomarkers is to compare 
multiple diseases (well-designed controls), to en-
sure high specificity. The trend is also shifting to-
wards using a panel of biomarkers for a disease, 
rather than just one biomarker which may not be 
as specific. A panel of biomarkers will tolerate nor-
mal variability that is observed among individuals, 
and that is due to the heterogeneous nature of the 
disease, without jeopardizing the diagnostic preci-
sion. Some of the proteins present in these bio-
marker panels may not contribute significantly to 
the overall specificity and sensitivity. Therefore, it 
is also necessary to optimize these panels, so that 
enough biomarkers are included to ensure diag-
nostic precision, while keeping costs down avoid-
ing testing for unnecessary biomarkers. Although 
there have been many advances in urinary prot-
eomics, these have not resulted in similar advance-
ments in clinical practice due to the difficulties 
mentioned above, which imply high costs and 
large data sets. In order to translate these poten-
tial biomarkers to clinical practice, vigorous valida-
tion is needed, with input from industry or large 
collaborative studies.
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